🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,838 results for “SP” Clear

  1. Succinylcholine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    the Effect of Succinylcholine on Barrier Pressure

    approved small molecule completed

    1 trial

  2. Sufentanil

    The First People's Hospital of Lianyungang

    Arteriovenous Malformation

    approved small molecule active

    1 trial

  3. Sugammadex hameln 100 mg/ml oplossing voor injectie, Naloxon HCl Accord 0,4 mg/ml, oplossing voor injectie / infusie in een voorgevulde spuit, ANEXATE 0,5 mg/5 ml, solution injectable (I.V.), REMIMAZOLAM , Sufentanil Viatris 5 microgram/ml oplossing voor injectie, Esmeron 10 mg/ml, oplossing voor injectie

    Disc Medicine

    General anesthesia

    approved small molecule active

    1 trial

  4. TACROLIMUS, SIROLIMUS, MYCOPHENOLATE MOFETIL, AZATHIOPRINE, PREDNISOLONE, EVEROLIMUS, MYCOPHENOLIC ACID, BELATACEPT, CICLOSPORIN

    The George Institute

    BK Polyomavirus DNAemia after kidney transplantation

    approved small molecule active

    1 trial

  5. TPO-RAs

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Primary Immune Thrombocytopenia (ITP)

    approved small molecule active

    1 trial

  6. Tacrolimus sustained-release capsule

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Renal Transplant Recipients

    approved small molecule completed

    1 trial

  7. Tamsulosin Oral Capsule

    The First People's Hospital of Lianyungang

    Ischaemic Heart Disease (IHD)

    approved small molecule completed

    1 trial

  8. Telbivudine treatment

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Chronic Hepatitis B

    approved small molecule completed

    1 trial

  9. Tenofovir Alafenamide 25 MG

    The First People's Hospital of Lianyungang

    Chronic Hepatitis C

    approved small molecule active

    1 trial

  10. Tenofovir Alafenamide Tablets

    The First People's Hospital of Lianyungang

    Chronic Hepatitis b

    approved small molecule active

    1 trial

  11. Tenofovir Alafenamide fumarate 25mg Oral Tablet

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Chronic Hepatitis B

    approved small molecule active

    1 trial

  12. Tenofovir disoproxil fumarate

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Chronic Hepatitis B

    approved small molecule active

    1 trial

  13. Test preparation：Methylcholine chloroacetate for inhalation

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Healthy People

    approved small molecule completed

    1 trial

  14. Test preparation：Methylcholine chloroacetate for inhalation

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Asthma

    approved small molecule completed

    1 trial

  15. Tetanusvaccin, suspensie voor injectie 40 IE

    Disc Medicine

    Systemic sclerosis, Systemic lupus erythematosus, Rheumatoid arthritis

    approved small molecule active

    1 trial

  16. Thalidomide

    The First People's Hospital of Lianyungang

    Gastric Cancer

    approved small molecule active

    1 trial

  17. The Placebo used for the clinical trial is a sterile saline solution (0.9% w/v solution of NaCl in water) supplied in 1.25 mL pre-filled glass syringes., Shingrix suspension for injection in pre filled syringe Herpes zoster vaccine (recombinant, adjuvanted), Shingrix powder and suspension for suspension for injection Herpes zoster vaccine (recombinant, adjuvanted)

    GlaxoSmithKline

    Incident dementia

    approved small molecule active

    1 trial

  18. The impact of extra-fine inhalation corticosteroid particles on small-airway disease in Chronic Obstructive Pulmonary Disease (COPD): a randomized, prospective cross-over trial.

    Pierre Fabre Australia Pty Ltd

    Chronic Obstructive Pulmonary Disease

    approved other active

    1 trial

  19. The placebo MDI is formulated as a suspension of spray-dried porous particles (consisting of 1,2-distearoyl-sn-glycero-3-phosphocholine [DSPC] and calcium chloride) in a hydrofluoroalkane propellant (HFA-134a). The placebo MDI uses the same excipients as active product but with absence of the active pharmaceutical ingredient (API)., Trixeo Aerosphere 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation, suspension

    AstraZeneca AB

    Chronic Obstructive Pulmonary Disease

    approved small molecule active

    1 trial

  20. The placebo has the same composition as the investigational medicinal product alkacitrat effervescent tablet 2 g/tab (with the exception of the active substance), is manufactured by the same manufacturer (uni-pharma kleon tsetis pharmaceutical laboratory s.a) and is not sterile., ALKACITRAT Αναβράζον δισκίο 2 g/tab

    Lacuna Pharma Pty Ltd

    Functional Dyspepsia

    approved small molecule active

    1 trial

  21. Thymosin Alpha 1

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Pancreatitis, Acute Necrotizing

    approved small molecule completed

    1 trial

  22. Ticagrelor

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Coronary Artery Disease

    approved small molecule completed

    1 trial

  23. Ticagrelor

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Coronary Heart Disease

    approved small molecule active

    1 trial

  24. Tiotropium 'Respimat' 5 mcg

    Universal Integrated

    Chronic Obstructive Airway Disease

    approved small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources